Key result
The Micra Transcatheter Pacing System demonstrated high implant success rates and significantly lower major complication rates compared to traditional transvenous pacemakers.
Why the study?
Traditional transvenous pacemakers carry persistently high implant-related complication and transvenous-lead failure rates despite technological advances.
Does the Micra Transcatheter Pacing System improve safety and efficacy compared to traditional transvenous pacemakers in patients with bradyarrhythmia?
Does the Micra Transcatheter Pacing System improve safety and efficacy compared to traditional transvenous pacemakers in patients with bradyarrhythmia?
The Micra leadless pacemaker offers a safe and effective alternative to traditional transvenous pacemakers, with high implant success and lower major complication rates.
Supports leadless pacing consideration in select patients; extends registry data but leaves open need for randomized confirmation.
Permanent cardiac pacemakers have traditionally comprised a surgically implanted subcutaneous pulse generator affixed to at least one transvenous pacing lead. Despite technological advances, implant-related complications and transvenous-lead failure rates have remained high. The Micra Transcatheter Pacing System is a miniaturized single chamber pacemaker that is implanted directly into the right ventricle, eliminating the subcutaneous pocket and creating a leadless pacemaker system. Registry data show an extremely high implant success rate, significantly lower major complication rates than transvenous pacemakers, stable pacing parameters and reliable battery performance. In this review we summarize the available clinical literature and highlight the promising efficacy and safety of the Micra Transcatheter Pacing System.
No takes yet. Share an insight, caveat, or question.
Wiles et al. (2018) conducted a review in Bradyarrhythmia. Micra Transcatheter Pacing System vs. transvenous pacemakers was evaluated. The Micra Transcatheter Pacing System demonstrated high implant success rates and significantly lower major complication rates compared to traditional transvenous pacemakers.